84 related articles for article (PubMed ID: 2348875)
1. EPO--one year later. The challenges for the social worker.
Antonoff A
Nephrol News Issues; 1990 May; 4(5):24, 29. PubMed ID: 2348875
[No Abstract] [Full Text] [Related]
2. EPO--one year later. Effects of EPO on nutritional status in CRF.
Schiro KB
Nephrol News Issues; 1990 May; 4(5):26, 34. PubMed ID: 2348876
[No Abstract] [Full Text] [Related]
3. EPO--one year later. Fighting anemia in the courtroom.
Riley JB; Pristave RJ
Nephrol News Issues; 1990 May; 4(5):27. PubMed ID: 2348877
[No Abstract] [Full Text] [Related]
4. The lessons of EPO rehabilitation.
Coutts L
Nephrol News Issues; 1990 May; 4(5):5, 28. PubMed ID: 2348878
[No Abstract] [Full Text] [Related]
5. [The cardiorenal anemia syndrome and treatment with EPO].
Karle H; Hansen NE
Ugeskr Laeger; 2006 Aug; 168(33):2686. PubMed ID: 16953546
[No Abstract] [Full Text] [Related]
6. What is EPO?
Farrington E
Pediatr Nurs; 1990; 16(5):471. PubMed ID: 2216572
[No Abstract] [Full Text] [Related]
7. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia.
Fujita Y; Inoue S; Horiguchi S; Kuki A
Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic target for the use of erythropoietin (EPO): is subnormal better than normal?].
Karle H; Hansen NE
Ugeskr Laeger; 2007 May; 169(19):1782-3. PubMed ID: 17537352
[No Abstract] [Full Text] [Related]
9. Erythropoietin, an update, and where to in the future?
Sulková S
EDTNA ERCA J; 1998; 24(3):30-2, 35. PubMed ID: 10392076
[TBL] [Abstract][Full Text] [Related]
10. Chronic occult intra-alveolar hemorrhage: a rare cause of failure to respond to erythropoietin.
Conlon PJ; O'Neill S; O'Neill G; Kelly F; Donohoe J
Clin Nephrol; 1994 Feb; 41(2):83-5. PubMed ID: 8004833
[TBL] [Abstract][Full Text] [Related]
11. Use of erythropoietin in Jehovah's Witness patients.
Jim RT
Hawaii Med J; 1990 Jun; 49(6):209. PubMed ID: 2397990
[No Abstract] [Full Text] [Related]
12. EPO adjuvant treatments: a need for more evidence.
Fishbane S
Am J Kidney Dis; 2006 Apr; 47(4):683-5. PubMed ID: 16564947
[No Abstract] [Full Text] [Related]
13. Erythropoietin for the anemia of chronic renal failure.
Schwartz AB; Prior J; Terzian L; Kahn B
Am Fam Physician; 1988 Jun; 37(6):211-5. PubMed ID: 3289343
[No Abstract] [Full Text] [Related]
14. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
van der Putten K; Braam B; Jie KE; Gaillard CA
Nat Clin Pract Nephrol; 2008 Jan; 4(1):47-57. PubMed ID: 18094727
[TBL] [Abstract][Full Text] [Related]
16. Catch a falling star: wonder drug EPO may be down, but not out.
Neumann ME
Nephrol News Issues; 2010 Sep; 24(10):8. PubMed ID: 20942325
[No Abstract] [Full Text] [Related]
17. [Treatment of renal anemia using synthetic human erythropoietin].
Blumberg A; Zehnder C
Ther Umsch; 1988 Dec; 45(12):895-9. PubMed ID: 3065970
[No Abstract] [Full Text] [Related]
18. EPO (epoetin) approval stirs cost concern in Congress.
Wagner M
Mod Healthc; 1989 Jun; 19(23):4. PubMed ID: 10293460
[No Abstract] [Full Text] [Related]
19. Effect of recombinant human erythropoietin on the anemia of chronic renal failure.
Urabe A; Takaku F; Mizoguchi H; Kubo K; Ota K; Shimizu N; Tanaka K; Mimura N; Nihei H; Koshikawa S
Int J Cell Cloning; 1988 May; 6(3):179-91. PubMed ID: 3397592
[TBL] [Abstract][Full Text] [Related]
20. [Biological similarity of erythropoietin: controlled maturation].
Combe C
Nephrol Ther; 2009 Feb; 5 Spec No1():1-2. PubMed ID: 19233074
[No Abstract] [Full Text] [Related]
[Next] [New Search]
